Cotrimoxazole prophylaxis increases resistance gene prevalence and α-diversity but decreases β-diversity in the gut microbiome of HIV-exposed, uninfected infants.
Prophylactic cotrimoxazole treatment is recommended in HIV exposed, uninfected (HEU) infants, but the effects of this treatment on developing HEU infant gut microbiotas and resistomes are largely undefined. We analyzed whole-metagenome sequencing data from 163 longitudinally collected stool samples from 63 HEU infants randomized to receive (n=34) or to not receive (n=29) prophylactic cotrimoxazole treatment. We generated taxonomic, functional pathway, and resistance gene profiles for each sample and compared microbiome signatures between cotrimoxazole treated HEU infants (CTX-T infants) and HEU infants not treated with cotrimoxazole (CTX-N infants). Metagenomic analysis did not reveal significant differences in taxonomic or functional pathway α-diversity between CTX-T infants and CTX-N infants. In contrast, resistance gene prevalence (p=0.00719) and α-diversity (p=0.0045) increased in CTX-T. These differences increased over time for both resistance gene prevalence measured by log normalized abundance (4 months mean 0.71, 95% CI [0.2, 1.2] and 6 months mean 0.85; 95% CI [0.1, 1.7]) and α-diversity (p=0.0045). Unlike α-diversity, interindividual gut microbiome taxonomic (mean -0.11; 95% CI [-0.15, -0.077]), functional taxonomic (mean -0.050; 95% CI [-0.084, -0.017]), and resistance gene (mean -0.13; 95% CI [-0.17, -0.099]) β-diversity decreased in CTX-T infants compared to CTX-N infants. These results are consistent with persistent antibiotic selection pressure. Cotrimoxazole prophylaxis in HEU infants decreased gut microbiome β-diversity and increased antibiotic resistance gene α-diversity and prevalence. Antibiotic resistance is a growing threat, especially in low- and middle-income countries where the higher perinatal HIV-exposure rates result in cotrimoxazole prophylaxis. Understanding effects from current HEU infant antibiotic prophylaxis guidelines will inform guideline revisions and efforts to reduce increasing antibiotic resistance.